IL120317A - Ciprofloxacin-hydrocortisone suspension - Google Patents

Ciprofloxacin-hydrocortisone suspension

Info

Publication number: IL120317A
Authority: IL; Israel
Prior art keywords: amount effective; hydrocortisone; ciprofloxacin; composition; aqueous
Prior art date: 1995-06-06

Application number

IL12031796A

Other languages

English (en)

Other versions

IL120317A0 (en

Original Assignee

Bayer Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-06

Filing date

1996-06-05

Publication date

2000-08-13

1996-06-05 Application filed by Bayer Ag filed Critical Bayer Ag

1998-06-15 Publication of IL120317A0 publication Critical patent/IL120317A0/xx

2000-08-13 Publication of IL120317A publication Critical patent/IL120317A/xx

Links

229960000890 hydrocortisone Drugs 0.000 title abstract 3
239000000725 suspension Substances 0.000 title abstract 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 abstract 3
230000000844 anti-bacterial effect Effects 0.000 abstract 2
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
229920001213 Polysorbate 20 Polymers 0.000 abstract 1
239000004372 Polyvinyl alcohol Substances 0.000 abstract 1
229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
239000002260 anti-inflammatory agent Substances 0.000 abstract 1
239000007864 aqueous solution Substances 0.000 abstract 1
235000019445 benzyl alcohol Nutrition 0.000 abstract 1
229960003405 ciprofloxacin Drugs 0.000 abstract 1
239000000470 constituent Substances 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
230000002209 hydrophobic effect Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
235000010445 lecithin Nutrition 0.000 abstract 1
239000000787 lecithin Substances 0.000 abstract 1
229940067606 lecithin Drugs 0.000 abstract 1
231100001200 nonototoxic Toxicity 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract 1
229920000136 polysorbate Polymers 0.000 abstract 1
229950008882 polysorbate Drugs 0.000 abstract 1
229940068977 polysorbate 20 Drugs 0.000 abstract 1
229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
239000000243 solution Substances 0.000 abstract 1
230000000699 topical effect Effects 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Dispersion Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Endoscopes (AREA)

IL12031796A 1995-06-06 1996-06-05 Ciprofloxacin-hydrocortisone suspension IL120317A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US46504895A	1995-06-06	1995-06-06

Publications (2)

Publication Number	Publication Date
IL120317A0 IL120317A0 (en)	1998-06-15
IL120317A true IL120317A (en)	2000-08-13

Family

ID=23846298

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12031796A IL120317A (en)	1995-06-06	1996-06-05	Ciprofloxacin-hydrocortisone suspension

Country Status (16)

Country	Link
US (1)	US5965549A (de)
EP (1)	EP0782448B1 (de)
CN (1)	CN1137685C (de)
AT (1)	ATE214931T1 (de)
AU (1)	AU708540B2 (de)
CA (1)	CA2199294C (de)
DE (1)	DE69620136T2 (de)
DK (1)	DK0782448T3 (de)
ES (1)	ES2173287T3 (de)
IL (1)	IL120317A (de)
MX (1)	MX9701731A (de)
NZ (1)	NZ309624A (de)
PT (1)	PT782448E (de)
TW (1)	TW464499B (de)
WO (1)	WO1996039146A1 (de)
ZA (1)	ZA964653B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6716830B2 (en)	1998-09-30	2004-04-06	Alcon, Inc.	Ophthalmic antibiotic compositions containing moxifloxacin
AR020661A1 (es) *	1998-09-30	2002-05-22	Alcon Lab Inc	Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US6509327B1 (en)	1998-09-30	2003-01-21	Alcon Manufacturing, Ltd.	Compositions and methods for treating otic, ophthalmic and nasal infections
AU6275999A (en) *	1998-09-30	2000-04-17	Alcon Laboratories, Inc.	Antibiotic compositions for treatment of the eye, ear and nose
US6395746B1 (en) *	1998-09-30	2002-05-28	Alcon Manufacturing, Ltd.	Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6500360B2 (en) *	1999-06-18	2002-12-31	Bernard Bendiner	Sorbic acid and/or its derivatives, such as potassium sorbate, as a preventative for rust, corrosion and scale on metal surfaces
US7064132B2 (en) *	1999-11-28	2006-06-20	Scientific Development And Research, Inc.	Composition and method for treatment of otitis external
US6156294A (en)	1999-11-28	2000-12-05	Scientific Development And Research, Inc.	Composition and method for treatment of otitis media
ES2160090B1 (es) *	2000-03-16	2002-07-01	Vita Invest Sa	Composiciones acuosas de ciprofloxacino, contenidas en envases monodosis y su utilizacion.
WO2002007704A2 (en) *	2000-07-26	2002-01-31	Alcon Universal Ltd.	Improved process for manufacturing compositions containing ciprofloxacin and hydrocortisone
BR0114104A (pt)	2000-09-25	2003-07-29	Bayer Healthcare Llc	Combinações microbianas óticas para tratamento de animais com membrana do tìmpano rompida
BR0212898A (pt)	2001-09-21	2004-10-13	Alcon Inc	Método de tratamento de infecções do ouvido médio
US7718189B2 (en)	2002-10-29	2010-05-18	Transave, Inc.	Sustained release of antiinfectives
US20040101506A1 (en) *	2002-11-25	2004-05-27	Fust Charles A.	Composition for the prevention and treatment of inflammation of the ear
US7842791B2 (en) *	2002-12-19	2010-11-30	Nancy Jean Britten	Dispersible pharmaceutical compositions
CN1761487A (zh) *	2003-03-20	2006-04-19	法玛西雅公司	抗炎剂的可分散制剂
US20050004098A1 (en) *	2003-03-20	2005-01-06	Britten Nancy Jean	Dispersible formulation of an anti-inflammatory agent
US20050009931A1 (en) *	2003-03-20	2005-01-13	Britten Nancy Jean	Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20040214753A1 (en) *	2003-03-20	2004-10-28	Britten Nancy Jean	Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
RU2329064C2 (ru) *	2003-07-31	2008-07-20	Фармация Энд Апджон Компани Ллс	Диспергируемая фармацевтическая композиция для лечения мастита и поражений уха
CA2533101A1 (en) *	2003-07-31	2005-02-03	Pharmacia & Upjohn Company Llc	Dispersible formulation of an anti-inflammatory agent
US8940321B2 (en)	2003-12-12	2015-01-27	Otic Pharma Ltd.	Compositions for treatment of ear disorders and methods of use thereof
US8030362B2 (en) *	2003-12-12	2011-10-04	Otic Pharma Ltd.	Compositions for treatment of ear disorders and methods of use thereof
US20060019987A1 (en) *	2004-07-23	2006-01-26	Fust Charles A	Methods and compositions for inhibiting, destroying, and/or inactivating viruses
JP5324223B2 (ja)	2005-12-08	2013-10-23	トランセイブ，インク．	肺感染症を治療する抗感染薬の脂質ベースの組成物及びその使用法
US20100196455A1 (en)	2007-05-04	2010-08-05	Transave, Inc.	Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9114081B2 (en)	2007-05-07	2015-08-25	Insmed Incorporated	Methods of treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en)	2007-05-07	2015-09-01	Insmed Incorporated	Method of treating pulmonary disorders with liposomal amikacin formulations
UA111147C2 (uk) *	2009-11-11	2016-04-11	Байєр Б.В.	Способи та композиції для лікування або профілактики зовнішнього отиту
DK2366408T3 (da)	2010-03-01	2012-10-22	Salvat Lab Sa	Vandige, klare opløsninger af fluocinolonacetonid til behandling af inflammation i øret
HU227743B1 (en) *	2011-07-22	2012-02-28	Debreceni Egyetem	Eardrop composition and process for producing this
MX2014006803A (es) *	2011-12-09	2014-07-09	Lupin Ltd	Composiciones farmaceuticas topicas de agentes antimicrobianos y agentes antiinflamatorios.
MX2015006681A (es)	2012-11-29	2016-04-06	Insmed Inc	Formulaciones de vancomicina estabilizadas.
SMT202000516T1 (it)	2014-05-15	2020-11-10	Insmed Inc	Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari
US9393243B1 (en)	2015-07-14	2016-07-19	Nilesh Parikh	Topical Ciprofloxacin compositions
WO2019191627A1 (en)	2018-03-30	2019-10-03	Insmed Incorporated	Methods for continuous manufacture of liposomal drug products
WO2019213398A1 (en)	2018-05-02	2019-11-07	Insmed Incorporated	Methods for the manufacture of liposomal drug formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4025620A (en) *	1975-10-22	1977-05-24	Leo Pharmaceutical Products Ltd., A/S	Treatment of canine otitis and composition therefor
US4670444B1 (en) *	1980-09-03	1999-02-09	Bayer Ag	and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
DE3471639D1 (en) *	1983-03-31	1988-07-07	Payne Packaging Ltd	Improvements in or relating to tapes
DE3537761A1 (de) *	1985-10-24	1987-04-30	Bayer Ag	Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
DE3704907A1 (de) *	1987-02-17	1988-08-25	Bayer Ag	Topisch anwendbare zubereitungen von gyrase-inhibitoren in kombination mit kortikosteroiden
DE3902079A1 (de) *	1988-04-15	1989-10-26	Bayer Ag	I.m. injektionsformen von gyrase-inhibitoren
US5061729A (en) *	1988-06-08	1991-10-29	Biogal Gyogyszergyar	Pharmaceutical composition and process for preparing the same
US5271939A (en) *	1988-10-03	1993-12-21	Alcon Laboratories, Inc.	Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation
US5260073A (en) *	1990-05-21	1993-11-09	Norwich Eaton Pharmaceuticals, Inc.	Use of phenylpropanolamine as a mucus secretogogue in the upper airways
AU5599594A (en) *	1992-11-16	1994-06-08	Ciba-Geigy Ag	Polyvinyl alcohol/borate ophthalmic drug delivery system
US5422116A (en) *	1994-02-18	1995-06-06	Ciba-Geigy Corporation	Liquid ophthalmic sustained release delivery system
ES2088742B1 (es) *	1994-06-29	1997-03-16	Salvat Lab Sa	Composicion antibiotica de aplicacion otica.

1996
- 1996-06-05 ES ES96917172T patent/ES2173287T3/es not_active Expired - Lifetime
- 1996-06-05 MX MX9701731A patent/MX9701731A/es unknown
- 1996-06-05 NZ NZ309624A patent/NZ309624A/en not_active IP Right Cessation
- 1996-06-05 WO PCT/US1996/008864 patent/WO1996039146A1/en not_active Ceased
- 1996-06-05 EP EP96917172A patent/EP0782448B1/de not_active Expired - Lifetime
- 1996-06-05 AU AU59840/96A patent/AU708540B2/en not_active Expired
- 1996-06-05 DK DK96917172T patent/DK0782448T3/da active
- 1996-06-05 PT PT96917172T patent/PT782448E/pt unknown
- 1996-06-05 CN CNB96190870XA patent/CN1137685C/zh not_active Expired - Lifetime
- 1996-06-05 DE DE69620136T patent/DE69620136T2/de not_active Expired - Lifetime
- 1996-06-05 IL IL12031796A patent/IL120317A/xx not_active IP Right Cessation
- 1996-06-05 AT AT96917172T patent/ATE214931T1/de active
- 1996-06-05 CA CA002199294A patent/CA2199294C/en not_active Expired - Lifetime
- 1996-06-05 ZA ZA964653A patent/ZA964653B/xx unknown
- 1996-06-06 TW TW085106748A patent/TW464499B/zh not_active IP Right Cessation
1997
- 1997-02-18 US US08/801,891 patent/US5965549A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2199294C (en)	2000-09-19
DE69620136D1 (de)	2002-05-02
NZ309624A (en)	1999-04-29
CN1160999A (zh)	1997-10-01
EP0782448B1 (de)	2002-03-27
AU708540B2 (en)	1999-08-05
TW464499B (en)	2001-11-21
MX9701731A (es)	1997-10-31
HK1002552A1 (en)	1998-09-04
PT782448E (pt)	2002-07-31
CN1137685C (zh)	2004-02-11
CA2199294A1 (en)	1996-12-12
EP0782448A1 (de)	1997-07-09
EP0782448A4 (de)	1998-05-20
US5965549A (en)	1999-10-12
WO1996039146A1 (en)	1996-12-12
ZA964653B (en)	1996-12-12
IL120317A0 (en)	1998-06-15
ES2173287T3 (es)	2002-10-16
DK0782448T3 (da)	2002-07-08
AU5984096A (en)	1996-12-24
DE69620136T2 (de)	2002-08-01
ATE214931T1 (de)	2002-04-15

Legal Events

Date	Code	Title
2000-12-06	FF	Patent granted
2001-06-14	KB	Patent renewed
2002-07-25	KB	Patent renewed
2010-11-30	KB	Patent renewed
2014-06-30	KB	Patent renewed
2016-12-29	EXP	Patent expired

Publication	Publication Date	Title
IL120317A0 (en)	1998-06-15	Otic antibacterial compositions
CA2289717A1 (en)	1998-11-12	Novel therapy for constipation
WO1996028148A3 (en)	1996-11-14	Use of a r-nsaid in a protective composition for the treatment of colorectal cancer
RU94041223A (ru)	1996-10-20	Средство для лечения мотонейроновых заболеваний
EP1086702A3 (de)	2001-04-04	Botulinustoxine gegen Migränekopfschmerzen
FI980822A7 (fi)	1998-04-09	Farmaseuttinen koostumus vaikuttavan aineen iho- tai limakalvopintaan tai iho- tai limakalvopinnan läpi
CA2031880A1 (en)	1991-06-22	Combined anti-inflammatory agent
IE831611L (en)	1984-01-13	Topical anti-inflammatory compositions
CA2321560A1 (en)	1999-09-16	The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
WO2001030802A3 (en)	2002-02-14	Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
CA2107669A1 (en)	1993-08-08	Preparation for treating wounds and hemorrhoides
PT902789E (pt)	2002-07-31	Derivados de androsteno
MY111260A (en)	1999-10-30	Pharmaceutical composition for the treatment of nicotine dependence
AU2002231889A1 (en)	2002-08-06	Halogenated composition, method for preparing same and uses thereof
AU1865100A (en)	2000-07-31	Hyaluronate lyase used for promoting penetration in topical agents
KR950016760A (ko)	1995-07-20	치질 치료제
RU94045866A (ru)	1996-10-20	Применение бисфенилалкилпиперазинов для лечения расстройств, вызванных злоупотреблением веществами, способ лечения
CA2156481A1 (en)	1994-09-01	5-ht2 receptor antagonist compositions useful in treating venous conditions
HUP9902415A2 (hu)	1999-11-29	Azonnal felszabaduló szilárd beadási formák és eljárás azok előállítására
EP0906108A4 (de)	2000-12-06	Verfahren zur behandlung von herzversagen mit endothelin-antagonist.
WO1999065475A3 (en)	2000-04-06	Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
EP0799618A3 (de)	1997-11-12	Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
FR2754824B1 (fr)	1999-03-05	Nouvelle composition contenant du chitosan
PT1140001E (pt)	2005-09-30	Composicao para tratamento de queimaduras
WO1998014193A1 (en)	1998-04-09	The use of a substance p antagonist for the manufacture of a medicament for the treatment of ocular pain